Drug lookup
Drug reference

Lacidipine

Dihydropyridine calcium channel blocker (long-acting) · Antihypertensive, Antianginal

START
2 mg PO once daily
TYPICAL MAX
6 mg/day
STOP IF
Severe hypotension, worsening angina, or significant oedema
WATCH
BP, heart rate, peripheral oedema; avoid grapefruit
CDSCO approvedSchedule HATC C08CA09
Dose laddermg/d
2start4usual6max/day
Renal dose adjustmenteGFR mL/min/1.73m²
FULLNo dose adjustment at any eGFR90

KDIGO 2024 + manufacturer label

Pharmacokineticsplasma · t hours
1hONSET1.5hPEAK16h1dDURATION
ONSET
1h · BP effect
PEAK
1.5h · Tmax
16h ·
DURATION
1d · once-daily
EXCRETION
Mainly faecal; minor renal
route + CYP
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
Avoid unless essential; limited data.
FDA category + note
Top interactionssee all 5
  • Grapefruit JuiceSevereDatabaseKimi deep-research + Cla
  • Strong Cyp3a4 InhibitorsSevereDatabaseKimi deep-research + Cla

Mechanism

Highly lipophilic DHP that blocks L-type voltage-gated calcium channels in vascular smooth muscle, with slow membrane equilibration giving smooth, prolonged BP lowering and minimal reflex tachycardia.

Indications

Hypertension (mono- or combination)

Dosing

Adult
2 mg PO once daily; titrate every 2–4 weeks to 4 mg, max 6 mg/day.
Pediatric
Not established.
Renal adjustment
No adjustment.
Hepatic adjustment
Reduce starting dose / titrate cautiously in significant impairment.
Geriatric
Start 2 mg; titrate slowly.
Max dose
6 mg/day

Pharmacokinetics

Onset
BP effect within hours; full effect over 1–2 weeks
Peak effect
~30–150 min (variable Tmax)
Duration
~24 h
Half-life
~13–19 h
Bioavailability
~10% (extensive first-pass)
Protein binding
>95%
Metabolism
Hepatic CYP3A4
Excretion
Mainly faecal; minor renal (metabolites)

Contraindications

  • Cardiogenic shock
  • Recent MI / unstable angina
  • Significant aortic stenosis
  • Hypersensitivity

Side effects

Common
HeadacheFlushingPeripheral oedemaPalpitationsDizziness
Serious
  • Severe hypotension
  • Reflex tachycardia (less than short-acting DHPs)
  • Gingival hyperplasia (chronic)

Pregnancy & lactation

Pregnancy

Avoid unless essential; limited data.

Lactation

Limited data; caution.

Drug interactions

Grapefruit Juice
Severe
Database

Gut CYP3A4 inhibition

Avoid grapefruit

Source: Kimi deep-research + Cla

Strong Cyp3a4 Inhibitors
Severe
Database

Markedly increased lacidipine exposure

Avoid combination

Source: Kimi deep-research + Cla

Ciclosporin
Moderate
Database

Possible increased ciclosporin levels

Monitor ciclosporin level

Source: Kimi deep-research + Cla

Other Antihypertensives
Moderate
Database

Additive BP lowering

Monitor BP; titrate

Source: Kimi deep-research + Cla

Strong Cyp3a4 Inducers
Moderate
Database

Reduced lacidipine exposure

Use alternative; monitor BP

Source: Kimi deep-research + Cla

Related guidelines

Ask House about Lacidipine

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20